<DOC>
	<DOCNO>NCT00556023</DOCNO>
	<brief_summary>The purpose study determine safety tolerability different dose CP-675,206 combination gemcitabine determine maximum dose CP-675,206 well tolerate give combination gemcitabine patient advance pancreatic cancer .</brief_summary>
	<brief_title>A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated , Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients metastatic pancreatic cancer Patient must adequate bone marrow , liver kidney function Patient must Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Chemotherapy naive Inoperable pancreatic cancer Patient must receive prior systemic therapy pancreatic cancer Patient must previously receive antiCTLA4 therapy History chronic inflammatory autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>interventional</keyword>
	<keyword>dose-finding</keyword>
</DOC>